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ABSTRACT 
Mitral valve prolapse (MVP) is one of the most common forms of cardiac valve disease 
and affects 1 in 40 individuals worldwide. MVP can lead to arrhythmias, heart failure, 
and sudden cardiac death and 1 in 10 patients will require valve surgery. Surgery for 
MVP is now the fastest growing cardiovascular intervention in the Western world. As 
such, MVP carries a significant burden of morbidity and mortality. Our lab was the first 
to identify a cause for non-syndromic MVP using a combination of linkage analyses, as 
well as capture sequence of the linkage interval, to identify loss of function mutations in 
the cadherin gene, DCHS1. Two-hybrid screens were undertaken to further understand 
DCHS1 function and the RNA binding protein, LIX1L was identified as the only 
interacting protein. LIX1L binds and promotes miRNA processing through interactions 
as an RNA-binding protein and miRNAs. This leads us to the hypothesis: DCHS1-
regulated miRNA processing stabilizes the valve endocardium. Expression studies have 
corroborated this theory as DCHS1, LIX1L, and the microprocessor proteins are 
expressed in endothelial cells in the mitral valve. Cell culture data shows that a loss of 
DCHS1 compromises processing of target miRNAs through the microprocessor leading 
to a significant decrease in miRNA expression. Expression studies have also shown that 
loss of Dchs1 reduces valve endocardial stability, which may be caused by the loss of 
miRNAs. These studies illustrate the importance of DCHS1 effects on valve endocardium 
stabilization in MVP. Uncovering how these changes lead to clinically significant 

















 The heart is an essential organ in the human body that is the center of the 
circulatory system. It is comprised of four chambers: the left atrium, right atrium, left 
ventricle, and right ventricle. Each chamber is crucial to conducting how blood flows to 
keep an organism alive. The left and right sides of the heart contain their own pumping 
systems, but they are able to communicate effectively in order to optimize blood flow. 
The right atrium receives the deoxygenated blood from the body and pumps it to the right 
ventricle through the tricuspid valve. Subsequently, the right ventricle pumps the 
deoxygenated blood to the lungs through the pulmonary valve. The left atrium receives 
the oxygenated blood from the lungs and pumps it to the left ventricle through the mitral 
valve. The left ventricle then pumps the oxygen-rich blood through the aortic valve to the 
rest of the body (Buckberg, Nanda, Nguyen, & Kocica, 2018). 
 In our lab, we are focused on heart development and how improper heart 
development can lead to cardiac disease in a patient’s life. Specifically, we focus on 
cardiac valve development. As previously mentioned, there are four valves in the heart: 
the pulmonary valve, the aortic valve, the tricuspid valve, and the mitral valve. Each 
valve functions to promote unidirectional blood flow through the heart. If there is any 
disruption to this process, such as incorrect valve development, this can lead to valve 
diseases such as mitral valve prolapse. My research aims to establish a mechanism by 
which mitral valve prolapse is caused. This is important to provide additional information 
to recent studies because it provides a mechanism for understanding the fundamental 
molecular and developmental processes that can be applied to the disease. The following 
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chapters will address our recent developmental, genetic, and molecular findings regarding 
valvular development and mitral valve prolapse. 
 
 
Figure 1.1 The Gross Anatomy of the Human Heart. The human heart is comprised of four 
chambers: the left atrium, right atrium, left ventricle and the right ventricle. The left and the right 
side of the heart have their own pumping systems. The right atrium receives deoxygenated blood 
from the body and pumps it to the right ventricle through the tricuspid valve. The right ventricle 
then pumps the deoxygenated blood to the lungs through the pulmonary valve. The left atrium 
receives the oxygenated blood from the lungs and pumps it to the left ventricle through the mitral 
valve. The left ventricle pumps the oxygen-rich blood through the aortic valve out to the rest of 
the body (Drawing by Rebecca Stairley, Norris Lab).  
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Valve Development 
 The human heart consists of four chambers (right atrium, right ventricle, left atrium, and 
left ventricle), and four valves (aortic and pulmonic semilunar), mitral and tricuspid valves. For 
the purpose of this study, we focus on the mitral valve leaflets.  The mitral valve leaflets are 
located between the left atrium and the left ventricle. The structure of the leaflets plays an 
important role for the proper function of the heart (Figure 1.1). The valves work together to 
optimize and maintain unidirectional blood flow throughout the heart (Horne et al, 2015). The 
mitral valve leaflets are enclosed with valvular endothelial cells (VECs), while the remaining 
volume of the leaflet is comprised of valvular interstitial cells (VICs) (Hinton et al.  2006) 
(Rabkin-Aikawa, Farber, Aikawa, & Schoen, 2004). 
 Valve development starts from a cardiac tube that is made of myocardium and 
endocardium. Between these two layers is a region called the cardiac jelly which is made of 
space-filling proteoglycans (Person, Klewer, & Runyan, 2005). The myocardium discharges a 
variety of growth factors that induce the endothelium to undergo endothelial-to-mesenchymal 
transformation (EMT). This results in the cardiac jelly being invaded by mesenchyme to initiate 
the first phase of valve development. This process is crucial in defining correct valve formation. 
As the valves continue to grow and stretch into the left ventricle, the fibrous leaflets become 
thinner, increasing the extracellular matrix (ECM) deposition and remodeling. It is not until 
several days after birth of a newborn that highly organized and distinct layers that represent the 
ECM are seen. The ECM of the valve is composed of three stratified layers that are rich in 
collagens, proteoglycans and elastin. Both mouse and human valves have these boundaries 
although there is variation on how many ECM zones exist. The complete valve maturation and 




Figure 1.2 Endocardial to Mesenchymal Transition: Endothelial-to-mesenchymal transition 
describes the process by which endothelial cells transform into mesenchymal cells. It is 
associated with a loss of endocardial cell markers such as VE-cadherin, B-catenin, PECAM-1, 
Fik-1, and Tie-2 and the acquisition of mesenchymal cell markers such as FSP-1, MMP-2,9  
vimentin, a-SMA, collagen 1 and 3, thromobospondin, and PAI-1. Endothelial cells those their 






There have been abundant studies that have included the similarities between animal 
models and human anatomy. This information has been used to use make new discoveries in 
translational science. Therefore, the comparison of adult aortic valve leaflet structure and 
composition demonstrates similar stratification in humans, sheep, chickens, rabbits and mice 
(Combs & Yutzey, 2009). The process of valve formation is universal, accommodating the 
species in which they reside.  As an example, we see conserved valve cell regulatory mechanisms 
in the smallest species such as Drosophila (Lammers et al. 2017). 
 As we examine valve formation on a molecular level, we look to evaluate the endocardial 
cushion composition and how the study of valve development includes different signaling 
mechanisms. The first studies that identified EMT in the heart were through pioneering work 
from the laboratory of Roger Markwald (Markwald, Fitzharris, & Manasek, 1977). When chick 
cardiac explants were placed on collagen lattice, the endocardium was seen adopting migratory 
and invasive characteristics. However, when the myocardium was removed from these cultures, 
the endocardium failed to change its phenotype. This was the first evidence demonstrating that 
myocardial-secreted factors could induce an endothelial-to-mesenchymal transformation. From 
these seminal studies, concerted efforts have focused on identifying the myocardial initiating 
signals (Runyan & Markwald, 1983). Since then, major growth factors have been identified that 
regulate this EMT process, such as transforming growth factor beta (TGFb) and bone 
morphogenetic protein (BMP). Notch signaling, active in the endocardium, has also been defined 
as playing a critical role in EMT progression and can synergize with TGFb and BMP ligands 
(Garside, Chang, Karsan, & Hoodless, 2013). The endocardial-to-mesenchymal transition process 
occurs when subsets of atrioventricular (AV) and outflow tract (OFT) endocardial cells transform 
into a mesenchymal phenotype, which determines the anatomical placement where the valves will 
form within the primary heart tube (de Vlaming et al. 2012) 
 The process of valve development occurs in multiple steps. These steps include: the 
formation of the ECM, the migration of endocardial cells into the ECM, the event of cardiac 
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looping that induces endocardial cushion swellings, triggering the overpopulation of endocardial 
cushions (Markwald, Ftizharris, Bolender, & Bernanke, 1979) (Eisenberg & Markwald, 1995) 
and the formation of the stratified layers (proteoglycans, elastin and collagen) of the ECM. The 
cause of the enlargement results from the myocardium of specific regions of the primary heart 
tube, the AV junction and the OFT upregulate the secretion of the ECM. This process allows for 
cushion morphogenesis that induces a subset of AV and OFT endocardial cells to lose their 
junctions and adopt a mesenchymal-like phenotype as they migrate into the cardiac jelly (Person 
et al, 2005). Additionally, there have been studies that demonstrate the role that both the 
myocardial and endocardial derived signaling pathways affect endocardial cushion EMT and 
proliferation of valve progenitor cells (de Lange et al., 2004). This eventually forms the 
















Cell Types in the Mature Mitral Valve 
 Through the events of valve development, the valve becomes mature and has its 
own different cell types. There are two main cell types that make up the valves: the 
valvular interstitial cells (VICs) and the valvular endothelial cells (VECs). The VEC’s 
reside on the outer rim of the leaflets. It has been shown that any infiltration or breakage 
of this border can lead to valve disease (Butcher & Nerem, 2007), (Leask, Jain, & 
Butany, 2003), (Butcher & Markwald 2007) (El-Hamamsy et al., 2009). 
 The majority of each leaflet is composed of VIC’s. Their fibroblastic consistency 
aids in several different characteristics throughout the valve due to their various 
placements within the leaflets (Horne et a., 2015). The VIC’s essentially act as first 
responders: if given enough stress they have the capability of migrating and contracting 
rather than staying in their resting state. Their main role is to mediate and maintain the 
ECM structure, throughout the maturation of valve development. Any disturbances in the 
roles of either of these cell types can lead to unfavorable consequences that can affect the 
biochemical functions leading to diseases. The overall progression of valve development 
has many evolving steps and if there is a misstep at any event during the process there 










Figure 1.3 Myxomatous Degeneration in Valves.  Human posterior leaflets of control 
and DCHS1 p. R2330C were isolated, fixed and stained with Movat’s Pentachrome. 
Leaflet thickening, elongation and myxomatous degeneration is observed in the DCHS1 
p. R2330C leaflet compared to the control. Expansion of the proteoglycan layer (blue) 
and the disruption of the normal stratification of matrix boundaries is observed in DCHS1 
p. R2330C leaflets, because the cell types become mixed and disorganized. 
Blue=proteoglycan, Black=elastin, Red=Fibrin or cardiac muscle. Scale bars= 0.5cm 










Biochemical Influences  
 As the valve is undergoing maturation, addition factors can play a role on how the 
valves are able to perform their job accurately, for example biomechanical forces. In a 
fully developed heart, the act of blood flowing from the atrium to the ventricle represents 
blood going from an area with low pressure to an area that is high in pressure. Previous 
studies have stated that the biomechanical forces behind effectively beating of the heart 
during valve development influence the formation and matrix composition of the valves 
(Butcher, Mcquinn, Sedmera, Turner, & Markwald, 2007). During isovolumetric 
relaxation, an interval in the cardiac cycle, the pressure difference between the left atrium 
and the left ventricle causes the MV leaflets to open and allow blood to flow from the left 
atrium into the left ventricle during diastole (Giovanni et al., 2007). During this time, the 
left ventricle stays in a relaxed state, allowing it to maintain a positive transmitral 
pressure which aids in filling the ventricle without complications. Soon after active 
ventricular relaxation, the fluid begins its deceleration and the MV closes, preventing any 
backflow of blood into the atrium (Saige et al. 1994).  
 In addition, the leaflets of the mitral valve are connected to tendinous chords that 
attach to the left ventricular myocardium through the papillary muscle. These fibrous 
structures provide tension to the mitral leaflets. This along with several other mechanical 
systems keep the tissues from ballooning upward into the left atrium during ventricular 
systole. Furthermore, in vitro models have suggested that vortices, the region of blood 
that is fixed around an axis line, is crucial to the closing of the valve. The vortices are 
generated by ventricular filling and aid the partial closure of the MV following early 
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diastole and are essential for the closing of the valve. Without these vortices, the valve 
would not be able to close during ventricular contraction (Bellhouse & Reid, 1969). 
 
Developmental Basis of Disease 
 To start investigating valve disease, researchers have designed many studies 
surrounding genetic disorders found in large families and from previous work published. 
Researchers have found similarities in disease like Alzheimer’s and diabetes because of 
the same genetic anomalies surrounding these diseases and valve disease (Reitz et al., 
2007) In each instance there are gene mutations, these mutations are present at 
conception, which leads to inheritable traits passed from generation to generation in 
families and the diagnosis of these diseases appearing later in life. Identifying the genes 
and their function in familial disease is vital in understanding how mutations of these 
genes lead to disease. With mitral dystrophies, individuals in a family can show a high 
degree of variation in when they are diagnosed with the disease, despite the fact the 
affected individuals all carry the same mutation. It has been found that children with 
mitral valve prolapse (MVP) have been diagnosed as young as six years of age (Kyndt et 
al. 1998). Furthermore, this knowledge proposes that a patient’s genetic makeup could 
dictate the severity of the valve disease. This is key in investigating the complexity 
behind valve disease, as it could open the door for new therapeutic aids and the discovery 





Mitral Valve Prolapse 
 MVP is the most common form of cardiac valve disease and is a major health 
burden. The disease is characterized by the abnormal billowing of one or both of the 
mitral valve leaflets. Structurally the disease causes myxomatous degeneration and the 
valves experience an increase in proteoglycan accumulation, fragmented collagen and 
hyperplasia (Figure 1.3). This phenotype prevents the valve from functioning properly. In 
addition, this causes an imbalance of biomechanical forces that affects the correct 
positioning of the leaflets as well. 
 This disease affects 1 in 40 people worldwide, making its prevalence rate between 
2-3%. Based on this information, MVP is expected to afflict approximately 176 million 
people worldwide (Devereux et al., 1987). These staggering numbers have brought much 
needed attention to this disease, yet there are many factors surrounding MVP that are 
unknown. MVP can be either syndromic and recognized as a symptom of a recognized 
syndrome, like Marfan syndrome, or it can be non-syndromic occurring in isolation. 
The term, MVP was coined by Barlow in 1963 (Barlow & Pocock, 1963) when he 
detected mitral regurgitation in one of his patients when examining their heart through an 
angiography. MVP carries a significant burden of morbidity and mortality. There are no 
effective nonsurgical treatments for MVP and an incomplete understanding of its 
fundamental causes has hindered therapeutic efforts. While surgical techniques continue 
to improve, the number of surgical cases and associated mortality rates are increasing. 
Surgeries for degenerative mitral valve disease increased by more than 44% from 2011-
2016 and currently >90,000 mitral valve surgeries occur each year making it the fastest 
growing cardiovascular intervention in the United States (Coutinho & Antunes, 2017). 
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MVP can lead to arrhythmias, heart failure, and even sudden cardiac death, and 1 in 10 
patients will require valve surgery. Through various studies, it was found that MVP could 
be inheritable or a naturally occurring mutation, but the initial diagnosis of MVP left 
many patients undetected. 
 The Framingham Heart study detailed vital information found in the 
echocardiography of MVP patients. It was found that echocardiographers misinterpreted 
the phenotype because the position of the echo probe did not relay proper mitral valve 
geometry (Freed et al., 1999). Initially physicians were doing an apical view to obtain the 
correct orientation of the valve. When the probe was turned there was a representation of 
the myxomatous valve. Through this study physicians were able to develop a more 
efficient and precise way to diagnose MVP patients and also detect accompanying health 
defects with this disease like heart failure and atrial fibrillation.  
 Recent studies by our group have provided new hope in identifying MVP disease 
mechanisms, as we were the first to describe genetic causes for non-syndromic MVP 
(Durst et al., 2015) (Dina et al. 2015) (Table 1.1). Our group has studied the cilia gene, 
DZIP1, a gene that regulates ciliogenesis (Toomer, 2019). If a deleterious missense 
mutation of DZIP1 occurs in humans, it can cause autosomal dominant non-syndromic 
MVP. This was further confirmed in a mouse model that confirmed the pathogenicity of 
this mutation and revealed impaired ciliogenesis during development, which progressed 
to adult myxomatous valve disease and functional MVP. Through genetic studies our 




Table 1.1: Genes associated with MVP. Genetic anomalies associated with mitral valve 
prolapse in humans (Durst et al., 2015) (Dina et al. 2015) (Kyndt et al. 1998) (Le 












DCHS1 as a Focus 
 We have chosen to focus on uncovering its function in the mechanism of disease 
in patients with MVP. Using a combination of linkage analyses as well as exome capture 
sequencing, our lab has identified the loss of function mutations in the cadherin gene, 
DCHS1, that segregates with MVP in multiple families. Patients with DCHS1 missense 
mutations displayed autosomal dominant inheritance, which we have shown in multiple 
model systems to cause haploinsufficiency, or gene expression that is half the normal 
level, and disease phenotype (Durst et al. 2015). Disease inception was traced back to 
defects in valve morphogenesis. Recent strides by other groups have confirmed these 
findings and identified putatively damaging DCHS1 variants in as many as 24% of MVP 
patients (Clemenceau et al. 2018). These data revealed that DCHS1 mutations are 
prominently involved in MVP and underscore the importance for defining its role(s) in 
cardiac development and disease.  DCHS1 expression becomes restricted to VEC’s after 
birth suggesting a putative role for this cadherin in stabilizing the valve endocardium. 
These data are provocative and imply unique roles for DCHS1 in VECs as the 
endocardial cells begin to arrest EMT. 
 To gain an understanding of DCHS1 function in the mitral valves, we undertook 
an unbiased two-hybrid screen of a human heart cDNA library. After screening 110 
million clones with the cytoplasmic tail of human DCHS1 protein, we identified the RNA 
binding protein LIX1L (LIX1-Like) as the only interacting protein. These findings were 
bolstered by additional reports showing that LIX1L interacts with DCHS1 in other model 
systems (Bando et al. 2011) (Mao, Kucuk, & Irvine, 2009). Although not much is known 
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about LIX1L function, previous work has shown its ability to bind to miRNAs and 
regulates miRNA expression (Nakamura et al. 2015). 
 
Cell Junctions and RNAi 
 It is well-established that cadherins stabilize cell-cell junctions and propagate 
downstream signaling cascades through their cytoplasmic domains to regulate tissue 
morphogenesis (Maitre & Heisenberg, 2013). Recent reports have shown that cells 
stabilize their junctions and suppress EMT through a mechanism that involves cadherin 
proteins recruiting miRNA processing complexes to the membrane (Kourtidis et al, 2017) 
(Kourtidis & Anastasiadis, 2016) (Kourtidis et al., 2015). RNA localization has evolved 
as a mechanism of energy conservation and efficient regulation of protein signaling to 
enable rapid molecular and cellular adaptations to changes in environmental conditions 
(Niessing, Jansen, Pohlmann, & Feldbrugge, 2018) (Jansen, Niessing, Baumann, & 
Feldbrugge, 2014). 
The microprocessor catalyzes the first step of miRNA biogenesis through its core 
members DROSHA and DGCR8 (Gregory et al. 2004) (Ha & Kim, 2014) (Figure 1.4). 
DROSHA is a double stranded RNA-specific endoribonuclease and it is the enzymatic 
component of the microprocessor. DGCR8 is essential for delivering miRNAs to the 
complex. The complex then processes the initial miRNA transcripts called primary 
miRNAs (pri-miRNAs) into precursor miRNAs (pre-miRNAs), which are then fed into 
the Dicer-Ago2 complex to produce the mature miRNA products. Until recently the 
microprocessor and several accessory components of the RNAi machinery were thought 
to localize solely in the nucleus (Ha & Kim 2014). However, this dogma was challenged 
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by recent work, which revealed a functional microprocessor that is recruited by cadherin 
complexes to epithelial cell junctions (Kourtidis et al. 2015) (Kourtidis & Anastasiadis, 
2016). In the study we have used this information to develop testable hypotheses that will 
uncover key mechanistic insights into MVP pathogenesis at a cellular and molecular 
level. 
All of this information taken together leads to the hypothesis: DCHS1-regulated 












Figure 1.4 Overview of miRNA processing. miRNA maturation includes the production 
of the primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and cleavage 
of the pri-miRNA by the microprocessor complex Drosha–DGCR8 in the nucleus. The 
resulting precursor hairpin, the pre-miRNA, is exported from the nucleus by Exportin-5–
Ran- GTP. In the cytoplasm, the RNase Dicer in complex with the double-stranded RNA-
binding protein TRBP cleaves the pre-miRNA hairpin to its mature length. The 
functional strand of the mature miRNA is loaded together with Argonaut (Ago2) proteins 
into the RNA-induced silencing complex (RISC), where it guides RISC to silence target 
mRNAs through mRNA cleavage, translational repression or deadenylation, whereas the 











CHAPTER 2: INTERACTIONS AND LOCALIZATION OF A NOVEL MEMBRANE 
TETHERED MIRNA PROCESSING COMPLEX 
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Introduction 
 MVP is one of the most common cardiac diseases and it is the most common 
cardiac valvular disease. MVP can occur as part of a recognized syndrome such as 
Marfan syndrome, characterizing it as syndromic MVP, or it can occur in isolation in 
which case it is called non-syndromic MVP. Although genetic causes for some 
syndromic forms of MVP are known, the genetic underpinnings of the more common 
non-syndromic form of MVP, which affects 2-3% of the population, have remained 
elusive. MVP occurs when the mitral valve leaflets disrupt steady blood flow from the 
left atrium to the left ventricle. This happens when either one or both of the leaflets 
(posterior and anterior) balloon upward into the left atrium.  
Through the findings revealed in the Framingham Heart study, the diagnosis of 
MVP was fully understood, and scientists took a closer look into the genetics behind the 
disease. In 1999, researchers performed familial screens that identified the first locus 
associated with autosomal dominant MVP, MMVP-1. The locus is on chromosome 16p 
(Disse et al., 1999) and by performing several more screens that verified the 
heterogeneity of the disease, linkage analysis mapped to two loci. This was followed by 
more studies linking MMVP2 located on chromosome 11p15.4.  
Additionally, in 2007, the gene Filamin A was found to be linked to MVP because 
the of its involvement in X-linked myxomatous valvular dystrophy (Le Tourneau et al., 
2018; Toomer et al., 2019). These studies ignited researchers to delve more into this 
finding and search for more components that are responsible for MVP in patients. We 
now have compelling genetic and functional evidence that significantly advance our 
understanding of MVP pathogenesis. The gene DCHS1 (Durst et al., 2015) is well-known 
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for its encoding of calcium-dependent cell-cell adhesion molecules. Previous studies 
within our lab found that mutations in DCHS1 cause MVP (Durst et al. 2015). 
Additionally, a genome-wide association study has led scientists to observe genetic 
variants within these MVP patients (Dina et al., 2015). However, patients with rare 
syndromic diseases that stem from alterations in the structure and function of primary 
cilia (“ciliopathies”) have a higher prevalence of MVP, suggesting that primary cilia may 




To date, there has been a short list of genes that are implicated in MVP, some of 
which are: DCHS1, TNS1, LMCD1, and Filamin A-MVD. Specifically, DCHS1 mutations 
causes myxomatous valves. Furthermore, we studied the pedigree of three families with 
non-syndromic MVP to begin to identify crucial players involved with disease. Using a 
combination of linkage analyses as well as exome capture sequencing, our lab has 
identified the loss of function mutations in the cadherin gene, DCHS1, that segregates 
with MVP in multiple families (Figure 2.1). Patients with DCHS1 missense mutations 
displayed autosomal dominant inheritance, which we have shown in multiple model 
systems to cause haploinsufficiency and disease phenotype (Durst et al. 2015). Disease 
inception was traced back to defects in valve morphogenesis. 
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Figure 2.1 Pedigrees and mutation identification. (A,C,D) 3 families with inherited 
autosomal dominant non-syndromic MVP. Black shading=MVP in all pedigrees. 
Probands are indicated with an arrow. Mutations in DCHS1 were identified in each of 
these families. DCHS1 Genotypes: Family 1- c.7538G>A (p. R2513H), Family 2&3- 
c.6988C>T (p.R2330C). No genotype =individual was unavailable for study. (B,E) DNA 











To gain an understanding of DCHS1 function in the mitral valves, we undertook 
an unbiased two-hybrid screen of a human heart cDNA library, using the company 
Hybrigenics. The two-hybrid screen was designed to establish direct protein-protein 
interactions by a simple bait-prey concept that examines the physical interactions of the 
protein in question. This technology can uncover various protein as well as DNA 
interactions that can lead to a network of integrated components. We used the DCHS1 
protein as the “bait” to find interactions with the molecule. After screening 110 million 
clones with the cytoplasmic tail of human DCHS1 protein, we identified the RNA 
binding protein LIX1L (LIX1-Like) as the only interacting protein (Figure 2.2). Follow 
up co-IPs and additional two-hybrid screens defined LIX1L as interacting with a small 
region of the cytoplasmic tail of DCHS1. These finding were bolstered by additional 
reports showing that LIX1L interacts with DCHS1 in other model systems (Bando et al. 
2011) (Mao, Kucuk, & Irvine, 2009).  
Lix1L is an RNA-binding protein that has shown its ability to promote RNA 
expression (Nakamura, 2015). We hypothesize this occurs through an interaction with the 
microprocessor components DROSHA and DGCR8 (Kourtidis, 2017). DROSHA is a 
double-stranded RNA-specific endoribonuclease and is the enzymatic component of the 
microprocessor. DGCR8 is essential for delivering miRNAs to the complex.The complex 
then processes the initial miRNA transcripts called primary miRNAs (pri-miRNAs) into 
precursor miRNAs (pre-miRNAs), which are then fed into the Dicer-Ago2 complex to 
produce the mature miRNA products. Until recently, the microprocessor and several 
accessory components of the RNAi machinery were thought to localize solely in the 
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nucleus. However, this dogma was challenged by recent work, which revealed a 
functional microprocessor that is recruited by cadherin complexes to epithelial cell 
junctions (Kourtidis, 2017). This led us to our hypothesis that DCHS1-LIX1L 
interactions promote membrane tethering of the microprocessor (DROSHA and DGCR8), 
which clips pri-miRNA to generate pre- miRNA. pre-miRNA is further processed into 
mature miRNAs (Figure 2.3) 
 
 
Figure 2.2 DCHS1 Interaction with LIX1L.  Based on the information provided from 
the Hybrigenics two-hybrid screen (A) Number of LIX1L interacting clones identified 
and their regions (represented in amino acids). (B) Schematic depicting LIX1L, its RNA 




Figure 2.3 Working model of Dchs1-microprocessor interaction. Dchs1-Lix1L 
interactions promote membrane tethering of the microprocessor (DROSHA and DGCR8), 
which clips pri-mRNA (arrowheads) to generate pre-miRNA. pre-miRNA is further 
processed into mature miRNAs. We hypothesize that with a loss of DCHS or LIX1L, 
there will be a decrease in miRNAs associated with EMT suppression, as well as VE-











Dchs1 and Lix1L 
Expression studies, using immunohistochemistry (IHC), showing co-expression 
of Dchs1 with Lix1L in valve endocardium post-EMT morphogenesis were conducted. 
They were able to support our findings as DCHS1 and LIX1L are both only expressed in 
the VECs (Figure 2.4). Although not much is known about Lix1L function, previous 
work has shown its ability to bind to RNA and regulate miRNAs (Nakamura et al. 2015). 
 
 
Figure 2.4 Expression of Dchs1 and Lix1L in mitral valves at P0. Dchs1 and Lix1L 
show significant overlap in their expression in the valve endocardium AL, PL= anterior 









To further identify the relationship between DCHS1 and LIX1L we created a 
knockout mouse model, Dchs1 Rosa NfatC1 enhancer cre (DRE), to study the effect of 
the deletion of Dchs1 on Lix1L. We found that with the deletion of DCHS1, LIX1L was 
also removed from the valve (Figure 2.5). In the wild type mice, DCHS1 and LIX1L 
were both expressed in the immunohistochemistry stains in the valve endothelial cells. 
They then are downregulated in the Dchs1 knockout mice. This reinforces our findings 
from the two-hybrid screen that stated that DCHS1 and LIX1L interact because LIX1L is 


















Figure 2.5: Expression of Dchs1 and Lix1L in mitral valves at P0 in wildtype and 
Dchs1 knockout mice. Expression of DCHS1 (red) in the first column is lost in the 
Dchs1 KO mouse model in comparison to the wild-type. Expression of LIX1L (red) in 
the second column is lost in the Dchs1 KO mouse model in comparison to the wild-type 
model. These results further confirm the results of the two-hybrid screen. nucleus (Blue) 













DCHS1, LIX1L, and the Microprocessor 
 As previously stated, our hypothesis is DCHS1 binds to LIX1L, which binds to 
the microprocessor (DROSHA and DGCR8). To support this theory, DGCR8 and 
DROSHA were stained in wild-type E14 and P0 mice. We observe both DROSHA and 
DGCR8 concentrated at the valve endocardial cell membrane with very little expression 
evident within nuclei of VECs or VICs during fetal or neonatal timepoints (Figure 2.6). 






Figure 2.6 Expression of the microprocessor components in the mitral valve. IHC for 
DGCR8 DROSHA and PECAM at E14.5 and P0. Significant overlap of membrane 
stained PECAM with the microprocessor in the valve endocardium is observed (arrows). 







 Though the genetics behind MVP are still developing, the beginning of fully 
understanding which genes cause this disease are examined through our studies. The 
mechanism by which DCHS1 causes MVP is still not completely understood but as we 
take a closer look at DCHS1, LIX1L, and the microprocessor we begin to form a broad 
hypothesis that mechanisms from DCHS1 mutations result in MVP are directly related to 
LIX1L and the microprocessor. 
 These studies illustrate that interactions between DCHS1, LIX1L and the 
microprocessor are all present in the VECs in the wild-type mice, which leads us to 
believe that there may be interaction between them. With a mutation that results in a loss 
of DCHS1, LIX1L is lost as well, and this gives us a broad idea of how they are 
interacting, and that the mutation is significantly affecting the stability of LIX1L. We 
believe that the cadherin protein DCHS1, interacts with RNA binding protein LIX1L, 
which then interacts with the microprocessor components DROSHA and DGCR8, which 
affects endocardial stability. 
 Further experiments are needed to firmly understand these interactions. In 
particular, studies where Lix1L is knocked down in both a mouse model and a cell model 
should be conducted to confirm that loss of LIX1L wouldn’t result in a loss of DCHS1 
should be conducted. Further studies looking at the localization of the microprocessor 
components DROSHA and DGCR8 after the loss of DCHS1 to determine if a DCHS1 
mutation leads to loss of the microprocessor should also be conducted. Cell culture 
studies using VECs would also be beneficial to this research to be able to confirm the 










CHAPTER 3: DCHS1 REGULATES MIRNA PROCESSING AND STABILIZES THE 
ENDOCARDIUM THROUGH MIRNA PROCESSING 
 33 
 Introduction 
Processing of pri-miRNAs to pre-miRNAs is an essential step in miRNA 
biogenesis and is mediated by the microprocessor (Figure 2.3). Impaired function of the 
microprocessor results in attenuated processing of pri-miRNAs and in decreased levels of 
pre-miRNAs and their mature miRNA products. We have identified a set of 
downregulated mature miRNAs – miR-200c, let7e, let7g, and miR-24 – based on 
information from miRbase that showed that these miRs are involved in EMT suppression, 
in both the DCHS1 and LIX1L knockdown endothelial cells. We propose that DCHS1 
interacts with the microprocessor through LIX1L to regulate the processing of a subset of 
miRNAs because: (I) there is a molecular link between DCHS1 and LIX1L; and (II) 
LIX1L is a RNA-binding protein that regulates miRNAs (Nakamura et al. 2015). 
miR-200c belongs to the miR-200 family, which is believed to play an essential 
role in tumor suppression by inhibiting EMT (Korpal and Kang, 2008). If we are to 
incorporate this miR into our hypothesis it is likely that a decrease in DCHS1 leads to a 
decrease in LIX1L which leads to a decrease in the mislocalization of microprocessor 
components Drosha and Dgcr8, which would lead to decreased mir-200c, leading to 
increased EMT and therefore decreased endocardial stability. 
miR-Let7e and miR-Let7g have been shown to be downregulated in congenital 
heart disease and to target HMGA, which promotes EMT (Lee and Dutta, 2007). If we 
incorporate these miRs into our hypothesis it is likely that a decrease in DCHS1 leads to a 
decrease in LIX1L which leads to a mislocalization microprocessor components Drosha 
and Dgcr8, which leads to a decrease in miR-Let7e and miR-Let7e, which then increases 
HGMA, leading to increased EMT and decreased endocardial stability.  
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miR-24 has been found to be suppressed by TGF-B signaling (Sun et al., 2015). 
TGF-B can induce EMT, and therefore it is likely that this miR would decrease in the 
case of aberrant EMT . If we are to incorporate this miR into our hypothesis it is likely 
that a decrease in DCHS1 leads to a decrease in LIX1L which leads to a mislocalization 
components DROSHA and DGCR8, which would lead to decreased mir-24, leading to 




 An expression study was conducted to compare the DGCR8 and DROSHA 
expression in wild-type and Dchs1 knockout mice. The results from this study show that 
a mutation in the Dchs1 gene leads to disrupted polarity in the VEC cells as well as 
diffuse CD31 expression, which is indicative of junctional defects (Figure 3.1). There is a 
near total loss of membrane polarization of the microprocessor components, meaning 
they dissociate from the membrane. The results also indicate mislocalization of the 
microprocessor and potentially decreased functionality of the complex. This supports our 





Figure 3.1 DCHS1 Regulates localization of RNAi proteins at E15.5.  IHC of mitral 
valves from control (Dchs1+/+) and KO (Dchs1-/-) mice for DROSHA and DGCR8. In 
KO mitral valves, DGCR8 and DROSHA polarity is disrupted (arrows). There is near 
total loss of membrane polarization of the microprocessor. Asterisks show diffuse CD31 





 To confirm our hypothesis that miR-200c, miR-Let7g, miR-Let7e, and miR-24 
were affected by a mutation in Dchs1, qPCRs where conducted to show the difference in 
amount of these miRs in controls versus Dchs1 knockdowns and Lix1L knockdowns in 
human umbilical vein endothelial cells (HUVECs) (Figure 3.2 and 3.3). The results show 
significant differences between the control to the Dchs1 knockdown and an even greater 
decrease from the control to the Lix1L KD. This supports the hypothesis that Dchs1 
mutations lead to mislocalization of the microprocessor and therefore potentially 











Figure 3.2: DCHS1 and LIX1L regulate miRNA expression of miR-200c, miR-
Let7e, and miR- Let7g. qRT-PCR showing miR-Let7e, miR-Let7g and miR-200c are 
downregulated in Dchs1 and Lix1L KD endothelial cells. There is a % fold decrease from 
the control to the Dchs1 KD and an even greater decrease from the control to the Lix1L 
KD. This supports the hypothesis that Dchs1 mutations lead to disruptions in miRNA-







Figure 3.3 DCHS1 and LIX1L regulate miRNA expression of miR-200c and miR-24 
qRT-PCR showing miR-24 and miR-200c are downregulated in Dchs1 and Lix1L KD 
endothelial cells. There is a % fold decrease from the control to the Dchs1 KD and an 
even greater decrease from the control to the Lix1L KD. This supports the hypothesis that 
Dchs1 mutations lead to disruptions in miRNA-processing and the hypothesis that LIX1L 





VEC stability through miRNAs 
 Mechanisms regulating valve endocardial stability post-EMT have previously 
been unknown. Failure to stabilize the endocardial epithelium can cause increased EMT 
and permeability of the endothelial barrier, or the ability to allow molecules in and out of 
the cell, which leads to defects that are associated with valvular heart disease (Lamouille, 
Xu, Derynck, 2014). This hypothesis is supported by our previously explained data (I) 
DCHS1, LIX1L and the microprocessor are primarily expressed by VECs during 
neonatal and adult timepoints. (II) We have identified miR-200c and miR-24 levels to be 
significantly decreased upon loss of DCHS1 and/or LIX1L (Figures 3.2 and 3.3). (III) 
Reduced expression of these miRNAs was anticipated as resulting in an increase in its 




 A western blot was conducted to determine if mutations in Dchs1 and Lix1L 
resulted in an increase to ZEB2, a master regulator of EMT and a transcriptional 
repressor of VE-cadherin (Figure 3.4). Array data from our Dchs1 KO mice and our 
Dchs1  KD cells revealed an increase in ZEB-2 coincident with Dchs1 and Lix1L 
knockdown VECs showing reduced VE-cadherin and increased ZEB2.  This supports the 
hypothesis that reduced expression of DCHS1 and LIX1L result in an increase in ZEB2 





Figure 3.4 Knockdown of DCHS1 and LIX1L:  Human VECs were infected with 
DCHS1 (A) or LIX1L (B) shRNA lentiviruses and put under selection. Western analyses 
show that stable cell lines exhibit a reduction in VE-Cadherin and diminished expression 
of DCHS1 and LIX1L. The transcriptional repressor of VE-cadherin, ZEB2 is increased 



















 An expression study was conducted to determine if Dchs1 knockout E15.5 mice 
have diffuse expression of CD31 and therefore decreased stability in the endocardium 
(Figure 3.5). The results show Dchs1 knockout mice have diffuse expression of CD31, 
which is consistent with altered endocardial structure and stability, and poorly established 
junctional connections. It is also apparent that CD31 is observed within the Dchs1 
knockout fetal valve interstitium which indicates aberrant EMT. 
 
 
Figure 3.5 Evidence for increased EMT in DCHS1 valves: Invading PECAM positive 
cells were observed in the Dchs1-/- (arrows) valves at E15.5, indicative of aberrant EMT. 









 With each of our findings, we come closer to understanding the role that DCHS1 
and LIX1L play in the disease genotype of MVP. Our significant findings indicate that 
loss of DCHS1 and LIX1L likely affect the microprocessor, and therefore miRNA 
biogenesis. Our studies show that losses of DCHS1 and LIX1L lead to a decrease in 
miRNAs that suppress EMT. This supports our hypothesis that loss of DCHS1 leads to 
loss of endocardial stability through an increase of aberrant EMT. Further studies should 
be completed to show that the decrease in miRNAs related to EMT suppression is greater 
than that of miRNAs that are unrelated to EMT. We were able to mark aberrant EMT in 
our knockout Dchs1 mice valves, however, lineage tracing using GFP and NfatC1-
enhancer cre, a cre line that only affects endocardial cells that do not undergo EMT, 
should be conducted to confirm the aberrant EMT. Though there is more work to do, our 
studies have laid the groundwork for future experiments and expanded the knowledge 
















 Mitral valve prolapse is one of the most common forms of cardiac disease, 
affecting approximately 1 in 40 people worldwide. Prolapsed valves result in 
regurgitation, arrhythmias and even sudden cardiac death in serve cases. The phenotype 
of a mitral valve prolapse, includes vales with myxomatous degeneration, that results in 
an increase in proteoglycans and fragmented collagen and hyperplasia 
 Currently, the only treatment for mitral valve prolapse is invasive surgery to 
replace or repair the valve. This can be both dangerous and expensive for the patient. 
While the disease is not completely understood, studies from our lab suggest that the 
cadherin protein DCHS1 plays a critical role in MVP. 
 Our genetic studies have revealed temporal-spatial expression patterns for the 
gene, Dchs1, in relationship to MVP. Using linkage and capture sequence of the linkage 
interval, our lab has identified loss of function mutations in the cadherin gene, DCHS1, 
which segregates with MVP in several families. Patients with DCHS1 missense mutations 
displayed autosomal dominant inheritance, which causes haploinsufficiency and disease 
phenotype (Durst et al. 2015). The disease origin was traced back to defects in valve 
morphogenesis. This data revealed that DCHS1 mutations are involved in MVP and 
emphasize the importance for defining its role(s) in cardiac development and disease. 
DCHS1 expression becomes restricted to VEC’s after birth suggesting a supposed role 
for this protein in stabilizing the valve endocardium. These data are interesting and imply 
unique roles for DCHS1 in VECs as the endocardial cells begin to end EMT. 
 To gain an understanding of DCHS1 function in the mitral valves, we undertook a 
two-hybrid screen of a human heart cDNA library. After screening 110 million clones 
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with the cytoplasmic tail of human DCHS1 protein, we identified the RNA binding 
protein LIX1L as the only interacting protein. We used this information to conduct our 
studies testing for the interaction of these two proteins. 
 Our studies have supported the data showing that DCHS1 and LIX1L interact. 
Through immunofluorescence studies we see that DCHS1 and LIX1L are expressed in 
only the valve endothelial cells. We also found that with a loss of DCHS1 in our Dchs1 
knockout mice, there was a loss of LIX1L as well. These data help to suggest the link 
between DCHS and LIX1L. We also studied the link between the genes Dchs1 and Lix1L 
with the microprocessor components DROSHA and DGCR8, since LIX1L has been 
confirmed to bind to RNA and regulate miRNA levels. Our expression study showed that 
expression of the microprocessor is restricted to the VECs which is consistent with the 
expression of DCHS1 and LIX1K. This, as well as localization of to the membrane 
provides evidence for a link between DCHS1, LIX1L, and the microprocessor. 
It has also been well-established that cadherins stabilize cell-cell junctions and 
propagate downstream signaling cascades through their cytoplasmic domains to regulate 
tissue morphogenesis (Maitre & Heisenberg, 2013). Recent reports have shown that cells 
stabilize their junctions and suppress EMT through a mechanism that involves cadherin 
proteins recruiting miRNA processing complexes to the membrane (Kourtidis et al, 2017) 
(Kourtidis & Anastasiadis, 2016) (Kourtidis et al., 2015). RNA localization as a method 
of energy conservation and regulation of protein signaling has changed to allow 
molecular and cellular changes to modifications. (Niessing, Jansen, Pohlmann, & 
Feldbrugge, 2018) (Jansen, Niessing, Baumann, & Feldbrugge, 2014). 
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The microprocessor catalyzes the first step of miRNA biogenesis through its core 
members DROSHA and DGCR8 (Gregory et al. 2004) (Ha & Kim, 2014). DROSHA is a 
double stranded RNA-specific endoribonuclease and it is the enzymatic component of the 
microprocessor. DGCR8 is essential for delivering miRNAs to the complex. The 
complex then processes the initial miRNA transcripts called primary miRNAs (pri-
miRNAs) into precursor miRNAs (pre-miRNAs), which are then fed into the Dicer-Ago2 
complex to produce the mature miRNA products. Until recently the microprocessor and 
several accessory components of the RNAi machinery were thought to localize solely in 
the nucleus (Ha & Kim 2014). However, this dogma was challenged by recent work, 
which revealed a functional microprocessor that is recruited by cadherin complexes to 
epithelial cell junctions (Kourtidis et al. 2015) (Kourtidis & Anastasiadis, 2016).  
We used this information to develop experiments to test DCHS1 regulation of 
miRNA processing and stabilization of the endocardium through miRNA processing. 
Using an expression study, we showed that loss of DCHS1 in mice leads to disrupted 
polarity and junctional defects, supporting our theories. We then conducted qPCR to 
determine if loss of DCHS1 and LIX1L leads to a decrease of miRs related to EMT 
suppression. We saw that each of our selected miRs had a decrease between the control 
and the Dchs1 knockout models. There was an even greater decrease from control to the 
Lix1L knockout model. These provides information to support the idea that a mutation 
that results in a loss of Dchs1 affects both miRNA processing and EMT.  
 Finally, we developed experiments to test VEC stability through miRNAs. Failure 
to stabilize the endocardial epithelium can cause increased EMT and permeability of the 
endothelial barrier, defects that have been associated with valvular heart diseases. 
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Reduced expression of these miRNAs was anticipated as resulting in an increase in its 
main target, ZEB2, a master regulator of EMT and a transcriptional repressor of VE-
cadherin.  
 We conducted a western blot to determine if there was a change in ZEB2 with the 
losses of DCHS1 and LIX1L in a knockout model. We saw an increase in ZEB2 and a 
decrease in VE-cadherin, which was consistent with our hypothesis, and a possible cause 
for increased EMT in the cells, and therefore decreased cell stability leading to MVP. An 
expression study to determine if Dchs1 knockout mice at  E1.5.5 have diffuse expression 
of CD31 and therefore decreased stability in the endocardium was conducted. The results 
showed diffuse expression of CD31, which is consistent with altered endocardial 
structure, stability, and poorly established junction.  
 Future studies should be conducted to further define the mechanism by which 
Dchs1 mutations cause MVP. The hope is that this information can be used in the future 
to develop therapies to treat this common but life threatening condition. The data 
provided gives a better understanding of the cellular and molecular cause of MVP as it is 





















Interactions and localization of a novel membrane tethered- miRNA processing 
complex in vitro in HuVECs. 
We tested the hypothesis that DCHS1 is required for membrane tethering of the 
RNAi microprocessor components DROSHA and DGCR8 through its interaction with 
LIX1L using an in vitro approach. Unfortunately, we were unable to achieve this data with 
human valve endothelial cells (HuVECs) as they proved difficult to grow, maintain, and 
infect, based on our unsuccessful trials as the cells are primary. We were unable to achieve 
knockdown cells. In the future, this experiment should be attempted again.  Western blot 
analyses of membrane and total cell preparations from each cell line should be used to 
quantify the subcellular levels of microprocessor proteins (DROSHA and DGCR8). 
Additionally, confocal microscopy should be paired with 3D immunocytochemistry (ICC) 
to identify whether apical/basal polarity of the complex is altered in the knockdown cells. 
Confocal data will be used to calculate the Manders coefficient for co-localization of 
microprocessor complex at WGA-stained membranes as we’ve shown previously.  To 
validate a direct effect of the DCHS1-LIX1L complex on localization of the 
microprocessor, rescue experiments should be performed. Electroporation of an epitope-
tagged mouse full-length DCHS1 construct (which will not be downregulated in the 
DCHS1-shRNA stable cells) or a construct that lacks the Lix1L interaction motif into 
DCHS1 KD VECs should occur. Reciprocal experiments should be performed by 
electroporating an epitope-tagged full length murine LIX1L construct or one that lack the 
DCHS1 interaction domain into our human LIX1L KD VECs. Both constructs will have 
an iRES-eGFP insert for ease of visualizing transfectants. Quantification of western 
analyses from membrane preparations and ICC should determine whether re-expression of 
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these mutant proteins (or control full length proteins) can rescue expression levels and 
membrane localization of the microprocessor.  
Co-immunoprecipitation 
If the binding of DCHS1 to LIX1L is required for interaction with the 
microprocessor, then immunoprecipitating DCHS1 should also “pull-down” the 
microprocessor complex and be visualized by Western blotting. To ensure specificity, we 
should perform reversible cross-linking of the complex. This should initially be tested in 
our control human VECs to prove the interaction occurs. Following successful interaction 
results, we should pull down DCHS1 in LIX1L KD cells as well as in peptide treated cells 
and probe for the complex. If DCHS1 requires LIX1L as an intermediate to interact with 
the microprocessor, the interaction between DCHS1 and the complex should be 
impaired/lost in the KD or peptide treated cells. Rescue experiments (described above), 
should be performed once we confirm these interactions.  
 
Dchs1 regulation of miRNA processing in vitro 
The hypothesis is that DCHS1 interacts with the microprocessor through LIX1L to 
regulate the processing of a subset of miRNAs. This will be conducted in vitro, with 
HuVECs to determine the effects of the Dchs1 regulation of miRNA processing on cell to 
cell interactions. To establish that the processing of these miRNAs is indeed impaired at 
the level of the microprocessor, we should examine the levels of the pri-miRNA and the 
pre-miRNA of miRNAs: miR-24 and miR-200c by qPCR in DCHS1 and LIX1L KD 
VECs, DCHS1 peptide treated VECs and in KD VECs that have been rescued by Lix1l or 
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Dchs1 constructs. RNA-Crosslinking and Immuno-Precipitation (RNA-CLIP) experiment 
will also be performed. Using this approach, control VECs should be fixed in low 
Paraformaldehyde (PFA) dilution to covalently, but reversibly, crosslink RNA-protein 
complexes, which will then be immunoprecipitated with a DCHS1-specific antibody under 
stringent conditions. This experiment should: (I) confirm binding of DCHS1-regulated pri-
miRNAs (miR-24, miR200c) to a DCHS1-LIX1L-microprocessor complex; and (II) 
identify the entire DCHS1-RNA target repertoire. DCHS1 RNA-CLIP and DROSHA 
RNA-CLIP will also be performed in control, LIX1L KD and peptide treated cells to 
determine whether DCHS1-LIX1L interactions are critical for recruitment of these 
miRNAs to DCHS1 and/or DROSHA to enable miRNA processing.  
Dchs1 regulation of miRNA processing in vivo 
In the future, tests to determine DCHS1 regulation of miRNA processing in vivo 
will be conducted. The hypothesis is that DCHS1 interacts with the microprocessor through 
LIX1L to regulate the processing of a subset of miRNAs. This would be conducted by 
isolating RNA from mitral valve leaflets to further determine if loss of endocardial DCHS1 
and/or LIX1L results in dysmorphic valves and that there is a decrease in miRs related to 
EMT. Those miRNAs that are identified as being mis-processed will be validated in vivo 
by isolating RNA from anterior mitral valve leaflets at E12.5, the likely start of EMT, 
and/or P0 and performing qPCR for each specific target. The models to be used initially 
will be the global DCHS1 and LIX1L KO, heterozygote and compound mutant mice. 
However, we expect that the microprocessor complex is primarily restricted to valve 
endocardium after EMT, at which point we will observe mislocalization of DROSHA and 
DGCR8 in the Dchs1 KO mice. miRNA processing defects in the valve endocardium will 
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be assayed in conditional het, KO and compound Dchs1/Lix1L mice using the Nfatc1-
Enhancer-Cre, which is only active in Post-EMT endocardial cells. Laser capture of valve 
endocardium will be performed via standard methods, and qPCR of our previously selected 
miRNAs (mir-200c, Let-7e, Let7g, and miR-24) will be performed with controls being 5S 
rRNA and U6 snRNA. Quantification of mitral valve geometry (volume, surface area, 
length and width) will be performed to determine if loss of endocardial Dchs1 and/or Lix1L 
results in dysmorphic valves as anticipated. Quantification of aberrant EMT can be 
investigated in vivo by generating lineage trace models NfatC1-enchancer-cre Rosa-GFP 
mice, in the conditional Dcsh1 and Lix1L floxxed mice at P0 as well as by performing EMT 
assays. Once we identify that a compromised endocardium, our studies will evolve to 
include these studies. Additionally, experiments aimed at identifying direct or indirect roles 
of ZEB2 will be developed if we demonstrate involvement of this transcriptional repressor 
in endocardium stability.  
 
DCHS1 stabilizes the endocardium through miRNA processing 
The goal of this experiment should be to identify whether loss of DCHS1-LIX1L 
interactions reduce VEC stability through miRNAs. This hypothesis is supported by these 
findings:  DCHS1, LIX1L and the microprocessor are primarily expressed by VECs during 
neonatal and adult timepoints, our previously identified miRs, reduced expression of these 
miRNAs, DCHS1 KO mice diffuse expression of CD31, and CD31 observed on cells 
within the Dchs1 KD fetal valve interstitium, indicating aberrant EMT. We suspect this is 
a result in an increase in its main target, ZEB2, a master regulator of EMT and a 
transcriptional repressor of VE-cadherin. This can be tested using proteins collected from 
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mouse valve samples and a western blot to examine if there is increased expression of 
ZEB2 in the in vivo model. 
To test whether the VEC monolayer is compromised, we should initially perform 
trans-endocardial resistance (TER) on control, DCHS1 and LIX1L knockdown VEC lines 
using the ECIS® (Electric Cell-substrate Impedance Sensing) system. Rescue experiments 
should be performed with the goal of restoring levels of miRNAs using miR mimics as 
well as wildtype constructs for DCHS1 and/or LIX1L in both knockdown cell lines. Anti-
miRs (a-miRs) targeting miR-24 and miR-200c in wild-type VECs should also be tested to 
examine whether these phenocopy the potential TER defects in DCHS1 and LIX1L KD 
cells. Our selected miR levels will be quantified by qPCR and VE-cadherin, CD31 and 
ZEB2, will be quantified by qPCR, Western and ICC to determine if the impedance 
measurements are a function of reduced VE-cadherin and CD31 driven by the 
transcriptional repressor ZEB2 in a DCHS1, LIX1L, miR-dependent mechanism. 
Additional controls for our studies should test if transfection of mutant DCHS1 
constructs that impair LIX1L interactions or the DCHS1 peptide, which targets the LIX1L-
DCHS1 interaction fail to rescue potential differences in TER. This control experiment 
should test the function of the DCHS1 cytoplasmic tail in regulating endocardial stability 






























All mouse studies were performed under protocols previously approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Medical University of 
South Carolina. Prior to cardiac resection, mice were euthanized in accordance with the 
Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 
1996). Comparisons between sexes were evaluated and no significant differences were 
observed. As such, data is comprised of pooled sexes for all experiments 
 
Dchs1 knockout mice (DT mice) 
To acquire knock out DT mice, a male heterozygote and a female heterozygote, both for 
Dchs1 were bred, from our vivarium. This breeding occurred for several generation to 
achieve wildtype, heterozygous, and knock out Dchs1 mice. 
 
Dchs1 Rosa nfatc1 enhancer-cre mice (DRE mice) 
To acquire DRE mice, a doubly floxxed Dchs1female mouse was bred with a male Rosa 
positive NfatC1 enchancer-cre positive male mouse. The mice were bred for several 
generations to achieve wild type, heterozygous, and conditional knockouts. 
 
Histology and Immunohistochemistry  
Embryonic and neonatal tissues were processed for immunohistochemistry (IHC) from D 
and DRE (wildtype, heterozygous, and homozygous). IHC staining was performed on 5 
um thick sections from stages: E15.5, E19, and P0 mitral valves. For IHC, antigen 
retrieval was performed for 1 minute using antigen unmasking solution (Vector 
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Laboratories, Burlingame, CA, USA, Cat#H-3300) by pressure cooker (Cuisinart, 
Stamford, CT, USA). The following are the primary antibodies and their dilutions: Novus 
Dchs1 1:500, Novus Lix1L, 1:100, abcam Drosha 1:100, Sigma Actin 1:500, Dianova 
Pecam 1:50, abcam GFP 1:500, DSHB MF20 1:100, Novus Zeb1 1:500, Thermofisher 
Ve-Cadherin 1:100, and Sigma Dgcr8 1:100. Primary antibody was detected using the 
following fluorescent secondary antibody at 1:100 dilution: goat anti-mouse 568, goat 
anti-rabbit 568, goat anti-chicken 568, donkey anti-rat 488, and donkey anti-mouse 488. 
Nuclei were counterstained with Hoescht (Life Technologies, Cat #H3569, 1:10,000) for 
10 minutes and slides were cover-slipped with SlowFade mounting medium (Life 
Technologies, Cat#S36937). Fluorescence imaging was performed using Ziess Axio 
Imager.  
 
Confocal Microscopy  
Images were acquired using the Leica TCS SP5 AOBS confocal microscope system. 
(Leica Microsystems, Inc., 410 Eagleview Boulevard, Suite 107, Exton, PA 19341). Z- 
stacks were set by finding the highest and lowest depth with visible fluorescence and 
using the system optimized setting to determine steps. Z- stacks were then compiled to 
form maximum projection images.  
 
Cell Culture 
HUVEC (human umbilical vein endothelial cells) were acquired from the Kourtidis Lab. 
HuVEC (Human Valve endothelial cells) were shared by the Bischoff Lab at Boston 
Children’s Hospital. Both cell lines were cultured in a 37 dress celcius, 5% CO2 
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incubator, in their respective media. HUVEC media was EGM-2 from Lonza and HuVEC 
media was an EGM-2 Endothelial Cell Growth Medium-2 Bullet Kit from Lonza, with 
10% heat-inactivated fetal bovine serum, and 1% GPS. The Bullet Kit includes EGM-2 
and Singlequots of bFGF, VEGF, EGF, IGF-1, and ascorbic acid. The media was filtered 
before the addition of the Singlequots Hydrocortisone was removed from the bullet kit. 
The HuVEC media was aliquoted into 50 mL tubes and frozen to keep the media fresh. 
Media on the cells were changed every 2-3 days and cells were passaged by using EDTA 
trypsin when plates were approximately 80% confluent. 
 
ShRNA infection 
To begin shRNA infection, the cells were plated in 60 mm plates. The cells were 
approximately 40% confluent the day of the infection. There was an extra plate to use as 
the non-infected control. Once the cells were 40% confluent, medium was replaced in 
each place with 2 mls of fresh medium. Polybrene was added at 8ug/ml final (1:1000 
from a 8mg/ul stock). Plates were swirled to mix polybrene and leave in the hood for 3-5 
minutes. 0.5 ml virus was added and incubated O/N at 37°C. 24 hours post infection 
media was changed, and the cells were split if they were reaching 80-90% confluency. 48 
hours post infection, the antibiotic selection with puromycin began, the amount 
determined by a kill curve. The cells were split again if they were approaching 80-90% 
confluency. The old plates were bleached if the cells were split. The cells were cultured 
until puromycin killed all of the cells in the non-infected control. The antibiotic dose was 




RIPA buffer was used for protein isolation. 400 ul of RIPA were used for 100 mm plate 
and 250 ul were used for a 60 mm plate. To create RIPA cocktail a 1:100 dilute of 
protease inhibitor cocktail and 1:100 of phosphatase inhibitor to the RIPA buffer was 
added. Ice was ready, and plates were washed with ice cold PBS twice. The RIPA was 
added to the plates and a cell scraper was used to scare cells (used 1 scraper per plate). 
Protein lysate was added to syringe and the plunger was used to pass the cells through the 
needle to homogenize further. The cells were kept on ice. The tubes were spun at 15000 
rpm for 5 minutes at 4°C. The supernatant (minus pellet) was collected into fresh tubes 
and stored at -20°C or immediately used for BCA assay. 
 
BCA Assay 
The equations for the BCA assay are as follows: (9 stds + (number of assays+1)) x 2 x 
0.2 ml=X and X/51=Y. Y ul of solution B of the BCA kit is added to (X-Y) of A solution 
to makeup the BCA solution. 10 ul of standard in a row and duplicated in another were 
added to a 96 well plate. 10 ul of each sample were added in duplicate. 200 ul of BCA 
assay solution was added and the plate was kept in the dark at 37°C for 30 minutes. 
Plates were read at 594 nm on a plate reader.  
 
Western Blot 
The protein concentration was calculated based on the BCA results. A water was set up 
and 80 ul of protein lysate and 20 ul of 10x Laemmli Buffer were mixed in a separate 
tube. Samples were boiled for 5 minutes, spun down and left at room temperature for 
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loading gels. A 4-20% gradient readymade BIORAD Gel was used. 1x electrophoresis 
buffer was made from 10x stock and Millipore water. The ladder was thawed on ice. The 
gel was loaded in the cassette and the green tape was removed. The buffer was poured 
into the cassette until it reached the line of the appropriate number gels. The samples and 
ladder were loaded into the wells. The samples were loaded according to the BCA assay. 
The gel was run at 200 V for approximately 30-40 minutes or until the ladder just runs 
out of the gel. The gels were transferred using the TURBO transfer unit using transfer 
buffer, transfer membrane kit, and the mid-molecular weight settings. The membrane was 
then blocked using 3% milk in TBST for 30 minutes at room temperature on a shaker. 
Primary and secondary antibody were in 3% milk in TBST. The primary antibody 
solution was added to the membrane and incubated at 4°C overnight while rotating. The 
next day the membrane was washed 3 times in TBST for 15 minutes each. The secondary 
antibody was then added and incubated at room temperature for 1 hour. The membrane 
was then washed 3 times using TBST for 15 minutes each. The 1:1 ECL solution was 




A Purelink RNA isolation kit from Thermo Fisher that contained all of the necessary 
materials was used to conduct this experiment. Trizol was kept at room temperature for 
10-15 minutes. The media was aspirated quickly off the cell plates. 1 ml of trizol was 
added for 60-100 mm plates. The trizol was evenly spread and left on for 5 minutes. The 
mixture was pipetted up and down several times to homogenize the cells. The cells were 
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collected and kept at -80°C or used to proceed to the RNA extraction kit. 200 ul of 
chloroform were added per every 1 ml of trizol. The mixture was shaken vigorously and 
kept at room temperature for 5 minutes. The mixture was then centrifuged at 6°C and 
15000 rpm for 15 minutes. The top phase was collected and moved to a fresh tube. Equal 
volumes of EtOH was added and then mixed by inverting. Half of the solution was 
transferred to a spin down column. The sample was spun at max speed for 1 minute and 
the flow through was discarded. This step was repeated until all of the sample is used. 
DNAase mixture was prepared for 80 ul per sample using 10x DNAase buffer, 
resuspended DNAase, and RNA free water. 350 ul of Wash 1 buffer was added to the 
tube and spun at 12000 rom for 15 seconds and the flow through was discarded. 80 ul of 
DNAase mixture was added to the column and incubated at room temperature for 15 
minutes. 350 ul of Wash 1 buffer was added to the column and spun down at 12000 rpm 
for 15 seconds and the flow through was discarded. 500 ul of wash II was added to the 
column and spun down at 12000 rpm for 15 seconds two times. The tube was spun down 
again at 15000 rpm for 2 minutes and rid of any flow through. Add RNAase free water 
and incubate at room temperature for 5 minutes. Spin down and collect in new tube to get 
the final RNA sample. 
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